|
Toggle Summary
November 3, 2021
|
Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as Monotherapy for the Treatment of Negative Symptoms in Patients with Schizophrenia in Advance of Potential NDA Submission
WALTHAM, Mass. , Nov. 03, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that the U. S.
|
Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as Monotherapy for the Treatment of Negative Symptoms in Patients with Schizophrenia in Advance of Potential NDA Submission
|
|
Toggle Summary
November 1, 2021
|
Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8
Management to Host Conference Call WALTHAM, Mass. , Nov. 01, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences , Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
|
Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8
|
|
Toggle Summary
October 11, 2021
|
Minerva Neurosciences Announces Promotion of Geoff Race to President
Frederick Ahlholm is Named Chief Financial Officer as Company Prepares to Submit a Pre-NDA Meeting Request to FDA WALTHAM, Mass. , Oct. 11, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to
|
Minerva Neurosciences Announces Promotion of Geoff Race to President
|
|
Toggle Summary
September 30, 2021
|
Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia
Company to Request Pre-NDA Meeting with U.S. Food and Drug Administration WALTHAM, Mass. , Sept. 30, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders,
|
Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia
|
|
Toggle Summary
September 8, 2021
|
Minerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and Head of Research & Development
Dr. Jay Saoud, Head of Research & Development, to retire from his current role and transition to an advisory role in which he will continue to support the preparation and planned submission of a New Drug Application (NDA) for Minerva’s lead program, roluperidone WALTHAM, Mass. , Sept.
|
Minerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and Head of Research & Development
|
|
Toggle Summary
August 2, 2021
|
Minerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates
WALTHAM, Mass. , Aug. 02, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the
|
Minerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates
|
|
Toggle Summary
July 26, 2021
|
Minerva Neurosciences to Report Second Quarter 2021 Financial Results and Business Updates on August 2, 2021
Management to host conference call WALTHAM, Mass. , July 26, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
|
Minerva Neurosciences to Report Second Quarter 2021 Financial Results and Business Updates on August 2, 2021
|
|
Toggle Summary
June 10, 2021
|
Minerva Neurosciences to Present at JMP Securities Life Sciences Conference
WALTHAM, Mass. , June 10, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the virtual JMP
|
Minerva Neurosciences to Present at JMP Securities Life Sciences Conference
|
|
Toggle Summary
May 28, 2021
|
Minerva Neurosciences to Present at Jefferies Virtual Healthcare Conference
WALTHAM, Mass. , May 28, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the Jefferies
|
Minerva Neurosciences to Present at Jefferies Virtual Healthcare Conference
|
|
Toggle Summary
May 12, 2021
|
Minerva Neurosciences Reports First Quarter 2021 Financial Results and Business Updates
Top-line results from the open-label extension of phase 3 monotherapy trial of roluperidone for the treatment of negative symptoms of schizophrenia show continuous improvement in negative symptoms, improved functional ability, favorable safety profile and limited number of psychotic relapses over
|
Minerva Neurosciences Reports First Quarter 2021 Financial Results and Business Updates
|
